Skip to main content

Intomics Collaborates with Lundbeck

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Danish bioinformatics and systems biology firm Intomics said today that H. Lundbeck will use its research services for data analysis and integration in its drug development process.

Under the agreement, Intomics will provide Lundbeck with data analysis and systems biology expertise, methods, and tools for analyzing and integrating the large amounts of biological data it generates.

Lundbeck develops and markets drugs for treating central nervous system disorders, including depression, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, epilepsy, and insomnia.

"With our data-analysis capabilities and Lundbeck's expertise in the central nervous system area, we see a great synergy that has the potential to benefit patients with CNS related disorders," Intomics CEO Thomas Jensen said in a statement.

Financial terms of the agreement were not released.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.